| Protein Name | DNAJB7 |
|---|
| Full Name | DnaJ heat shock protein family (Hsp40) member B7 |
|---|
| Gene Symbol | [DNAJB7](/genes/dnajb7) |
|---|
| UniProt ID | [Q9Y4E5](https://www.uniprot.org/uniprot/Q9Y4E5) |
|---|
| Protein Family | Hsp40/DnaJ family |
|---|
| Molecular Weight | ~25 kDa |
|---|
| Subcellular Localization | Cytoplasm |
|---|
DNAJB7 (also known as MZB1 or ERDJ5) is a member of the DnaJ/Hsp40 family of molecular chaperones. These proteins play crucial roles in protein folding, quality control, and the cellular stress response. In the context of neurodegeneration, DNAJB7 and related Hsp40 family members have attracted attention for their ability to modulate protein aggregation, a hallmark of diseases like Alzheimer's disease and Parkinson's disease.
¶ Structure and Function
¶ Protein Domain Architecture
DNAJB7 contains several functional domains characteristic of the Hsp40 family:
- N-terminal J domain: Conserved domain that interacts with Hsp70 chaperones and stimulates their ATPase activity
- Glycine/phenylalanine (G/F)-rich region: Flexible linker region
- C-terminal client-binding domain: Binds to unfolded proteins and facilitates Hsp70-mediated refolding
- Cysteine string motif: Present in some DNAJB proteins, involved in protein interactions
DNAJB7 functions as a co-chaperone by:
- Recognizing misfolded proteins: The C-terminal domain binds to hydrophobic regions of unfolded proteins
- Recruiting Hsp70: The J domain delivers substrates to Hsp70 family proteins
- Stimulating ATP hydrolysis: Hsp70 ATP hydrolysis is stimulated, stabilizing the client protein
- Facilitating refolding or degradation: Depending on the cellular context, clients may be refolded or targeted for degradation
Neurodegenerative diseases are characterized by pathological protein aggregation:
DNAJB7 may modulate these aggregation processes.
In Alzheimer's disease, DNAJB7 may play protective roles:
- Amyloid-beta handling: DNAJB7 could potentially interact with APP processing intermediates
- Tau quality control: May assist in refolding or clearing hyperphosphorylated tau
- ER stress: DNAJB7 localizes to the endoplasmic reticulum, where it may mitigate ER stress
For Parkinson's disease, DNAJB7 involvement includes:
- Alpha-synuclein aggregation: Hsp40 family members can inhibit alpha-synuclein fibrillization
- ER stress response: PD is associated with ER stress; DNAJB7 may provide neuroprotection
- Protein quality control: Overall enhancement of cellular proteostasis
DNAJB7 and related Hsp40 proteins protect neurons through multiple mechanisms:
- Inhibition of aggregation: Direct binding to aggregation-prone proteins prevents fibril formation
- Facilitated refolding: Cooperation with Hsp70 refolds misfolded proteins
- Targeting for degradation: Delivery of irreversibly damaged proteins to the proteasome or autophagy system
- Stress granule dynamics: Involvement in stress granule assembly and disassembly
The Hsp70-Hsp40 system is an attractive therapeutic target:
- Small molecule activators: Compounds that enhance Hsp40-Hsp70 activity could boost proteostasis
- Gene therapy: Overexpression of DNAJB7 or related proteins
- Protein-based therapeutics: Recombinant Hsp40 proteins as neuroprotective agents
Key challenges remain:
- Blood-brain barrier: Therapeutic delivery to the CNS
- Specificity: Achieving selective modulation without disrupting normal proteostasis
- Dosage: Balancing chaperone activity with potential interference in normal protein function
While DNAJB7 genetic variants are not strongly associated with neurodegenerative disease risk, the broader Hsp40 family shows:
- DNAJC family: Some DNAJC genes have GWAS hits for PD and AD
- Modifying mutations: Rare variants in chaperone genes may modify disease onset or progression
The expression of DNAJB7 and related chaperones may serve as:
- Stress indicators: Elevated levels reflect cellular proteostatic stress
- Therapeutic response markers: Chaperone induction as a biomarker for drug efficacy
- Heat Shock Proteins in Neurodegeneration
- Protein Aggregation Mechanisms
- Molecular Chaperones
- Alzheimer's Disease Therapeutics
- Parkinson's Disease Therapeutics